Allergen immunotherapy — Competitive Intelligence Brief

Allergen immunotherapy (Allergen immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Immunology.

phase 2 Immunomodulator Immunology Biologic

Target snapshot

Allergen immunotherapy (Allergen immunotherapy) — Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.. Allergen immunotherapy works by gradually increasing exposure to specific allergens to build tolerance and reduce symptoms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Allergen immunotherapy TARGET	Allergen immunotherapy	Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.	phase 2	Immunomodulator
Tailored Group	Tailored Group	Beijing Children's Hospital	marketed	Immunomodulator
Lamivudine+Oxymatrine Capsules	Lamivudine+Oxymatrine Capsules	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor + herbal immunomodulator	Reverse transcriptase; oxymatrine targets multiple immune pathways (non-specific)
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Comarum Palustre	Comarum Palustre	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	herbal immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

1. Actavis Mid-Atlantic LLC · 1 drug in this class
2. Active Biotech AB · 1 drug in this class
3. Air Force Military Medical University, China · 1 drug in this class
4. Astellas Pharma Inc · 1 drug in this class
5. Bayer · 1 drug in this class
6. Beijing Children's Hospital · 1 drug in this class
7. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
8. Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
9. Chang Gung Memorial Hospital · 1 drug in this class
10. ALK-Abelló A/S · 1 drug in this class